Registry for people with hepatitis B infection
Part of Digestive system, Infections clinical trials.
This study is a registry, meaning it collects health information from people living with hepatitis B rather than giving a new treatment. It may help researchers better understand different hepatitis B groups and outcomes over time.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have hepatitis B infection
- For the chronic hepatitis B group: your hepatitis B test (HBsAg) was positive for at least 1 year
- For the chronic hepatitis B group: your HBeAg status has been documented for at least the last 6 months
- For the chronic hepatitis B group: you are age 70 or younger
- For the chronic hepatitis B group: you do not have HIV or hepatitis C infection with detectable virus (RNA positive)
- For the chronic hepatitis B group: you do not have significant other liver diseases, cirrhosis, or past liver cancer
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial looks at people with long-term hepatitis B infection and studies how treatment may affect health over time. It may help you understand whether your care improves outcomes for chronic hepatitis B.
This trial tests a new vaccine to treat chronic hepatitis B. It's for people who have been on antiviral medication for at least 6 months and still have a low level of the virus in their blood.
This study looks at the genes of people with chronic hepatitis B (HBV) to find why some people's immune cells (B cells and NK cells) stop working properly. The goal is to discover new ways to treat the disease.
This study collects a small sample of liver cells to understand how hepatitis B virus behaves in the liver and how the immune system responds. This could help improve future treatments for chronic hepatitis B.
This early-phase study tests whether a hepatitis B vaccine (with an added ingredient to boost the immune response) can safely help people with long-term hepatitis B who are already on antiviral therapy. It is mainly looking at safety and how the immune system responds.
This study builds a group of people to measure small hepatitis B “viral RNA” signals in the blood. The goal is to see if these measurements could help researchers find a functional cure and better understand who may respond over time.
Hear when a new Hepatitis B Virus Infection trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.